WallStreetZenWallStreetZen

NASDAQ: MLTX
Moonlake Immunotherapeutics Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

MLTX earnings and revenue history

Current Revenue
$0.0
Current Earnings
-$58.2M
Current Profit Margin
0%

MLTX Return on Equity

Current Company
-11.7%
Current Industry
22.8%
Current Market
33.8%
MLTX's Return on Equity (-11.7%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when MLTX announces earnings.

MLTX Return on Assets

Current Company
-10.9%
Current Industry
3.5%
MLTX is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

MLTX Return on Capital Employed

Current Company
-10.89%
Current Industry
21.4%
MLTX has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

MLTX vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
MLTX$0.00-$57.96M-$58.24MN/AN/A
MRUS$35.19M-$174.08M-$167.66M-0.15%N/A
RYTM$101.78M-$239.38M-$260.73M+689.92%N/A
FOLD$455.66M-$40.33M-$119.54M+28.23%N/A
DYN$0.00-$255.35M-$257.60MN/AN/A
View Top Biotech Stocks

MLTX earnings dates

Next earnings date
Nov 12, 2024

Moonlake Immunotherapeutics Earnings & Revenue FAQ

What were MLTX's earnings last quarter?

On Invalid Date, Moonlake Immunotherapeutics (NASDAQ: MLTX) reported Q2 2024 earnings per share (EPS) of -$0.39, up 69.57% year over year. Total Moonlake Immunotherapeutics earnings for the quarter were -$24.76 million. In the same quarter last year, Moonlake Immunotherapeutics's earnings per share (EPS) was -$0.23.

If you're new to stock investing, here's how to buy Moonlake Immunotherapeutics stock.

What was MLTX's earnings growth in the past year?

As of Q3 2024, Moonlake Immunotherapeutics's earnings has grown year over year. Moonlake Immunotherapeutics's earnings in the past year totalled -$58.24 million.

What is MLTX's earnings date?

Moonlake Immunotherapeutics's earnings date is Invalid Date. Add MLTX to your watchlist to be reminded of MLTX's next earnings announcement.

What was MLTX's revenue last quarter?

On Invalid Date, Moonlake Immunotherapeutics (NASDAQ: MLTX) reported Q2 2024 revenue of $0.00 up N/A year over year. In the same quarter last year, Moonlake Immunotherapeutics's revenue was $0.00.

What was MLTX's revenue growth in the past year?

As of Q3 2024, Moonlake Immunotherapeutics's revenue has grown null year over year. Moonlake Immunotherapeutics's revenue in the past year totalled $0.00.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.